Madrigal Pharmaceuticals stock reports 71 percent revenue growth in Q2

Published on 10/04/2026 at 23:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal Pharmaceuticals stock had more than 49,000 Rezdiffra patients on June 30, 2026. The October 2 price was USD 499.40 after Q2 revenue rose 71 percent.

MDGL, US5588681057, Illustration mit AI erstellt.

Madrigal Pharmaceuticals stock (ISIN US5588681057) was last at USD 499.40 on Nasdaq on October 2, 2026, down 0.06 percent from the prior close. The company’s Q2 2026 revenue reached USD 364.3 million, giving the commercial story a stronger base even as losses continued.

Revenue reaches USD 364.3 million

According to TradingView, Madrigal reported net revenue of USD 364.3 million for Q2 2026 on July 30, 2026, up 71 percent from USD 212.8 million in Q2 2025. The company posted a net loss of USD 57.9 million, or USD 1.99 per diluted share, during the quarter.

The revenue result also exceeded the USD 352.13 million analyst estimate cited by MarketBeat. That comparison puts the quarterly sales beat at USD 12.12 million, while the USD 1.99 loss per share was better than the USD 2.68 consensus loss.

Rezdiffra adoption expands

At the Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, management said Rezdiffra had more than 49,000 patients on therapy at the end of Q2 and crossed 50,000 patients in July, according to Investing.com. The same presentation described net patient additions of 6,000 to 7,000 per quarter and highlighted first-line commercial access without step edits.

The commercial progress comes with a financial trade-off. Investing.com reported that Madrigal expects gross-to-net pressure during 2026 as the business moves from no contracting to full commercial contracting, while Medicare contracting is expected in 2027.

Analysts see room above USD 499.40

Citigroup initiated coverage with a Buy rating and a USD 725 price target on September 23, 2026, while MarketBeat reported a Moderate Buy consensus from 18 analysts. The published average target was USD 710.20, which lies 42.2 percent above the October 2 Nasdaq price of USD 499.40.

The valuation case therefore depends on commercial execution rather than revenue alone. Madrigal held USD 838.9 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026, while its Q2 operating expenses reached USD 420.6 million, according to TradingView.

Stock remains below yearly high

MDGL was last at USD 499.40 on Nasdaq at 4:00 p.m. ET on October 2, 2026. Its session range was USD 491.05 to USD 505.00, and the 52-week range was USD 393.61 to USD 615.00, leaving the stock 18.80 percent below its yearly high.